Download PDF
Thromb Haemost 2012; 108(06): 1241-1243
DOI: 10.1160/TH12-07-0484
Letters to the Editor
Schattauer GmbH

Calcification inhibitors in vascular calciphylaxis associated with normal renal function

Vincent Brandenburg   *
1   Department of Cardiology, University Hospital Aachen, Aachen, Germany
,
Nadia Al-Fakhri   *
2   Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps-University, Marburg, Germany
,
Katharina Nemeth
2   Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps-University, Marburg, Germany
,
Claudia Goettsch
3   Division of Endocrinology,Diabetes, and Bone Diseases, Department of Medicine III, Dresden Technical University Medical Center, Dresden, Germany
,
Leon J. Schurgers
4   Department of Biochemistry, Cardiovascular Research Institute CARIM, University of Maastricht, Maastricht, The Netherlands
,
Cees Vermeer
5   VitaK, Cardiovascular Research Institute CARIM, University of Maastricht, Maastricht, The Netherlands
,
Lorenz C. Hofbauer
3   Division of Endocrinology,Diabetes, and Bone Diseases, Department of Medicine III, Dresden Technical University Medical Center, Dresden, Germany
,
Michael Schoppet
6   Department of Internal Medicine and Cardiology, Philipps-University, Marburg, Germany
› Author Affiliations
Further Information

Publication History

Received: 13 June 2012

Accepted after major revision:07 September 2012

Publication Date:
30 November 2017 (online)

    Permissions and Reprints

 

* These authors contributed equally.


 

  • References

  • 1 Brandenburg VM, Cozzolino M, Ketteler M. Calciphylaxis: a still unmet challenge. J Nephrol 2011; 24: 142-148.
    CrossrefPubMedGoogle Scholar
  • 2 Shanahan CM, Crouthamel MH, Kapustin A. et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697-711.
    CrossrefPubMedGoogle Scholar
  • 3 Nigwekar SU, Wolf M, Sterns RH. et al. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 2008; 3: 1139-1143.
    CrossrefPubMedGoogle Scholar
  • 4 Ketteler M, Bongartz P, Westenfeld R. et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833.
    CrossrefPubMedGoogle Scholar
  • 5 Cranenburg EC, Koos R, Schurgers LJ. et al. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost 2010; 104: 811-822.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Cranenburg EC, Vermeer C, Koos R. et al. The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res 2008; 45: 427-436.
    CrossrefPubMedGoogle Scholar
  • 7 Arenas MD, Gil MT, Gutiérrez MD. et al. Management of calcific uremic arteriolopathy (calciphylaxis) with a combination of treatments, including hyperbaric oxygen therapy. Clin Nephrol 2008; 70: 261-264.
    CrossrefPubMedGoogle Scholar
  • 8 Hristova M, van Beek C, Schurgers LJ. et al. Rapidly progressive severe vascular calcification sparing the kidney allograft following warfarin initiation. Am J Kidney Dis 2010; 56: 1158-1162.
    CrossrefPubMedGoogle Scholar
  • 9 Price PA, Faus SA, Williamson MK. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 2000; 20: 317-327.
    CrossrefPubMedGoogle Scholar
  • 10 Baldwin C, Farah M, Leung M. et al. Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis 2011; 58: 988-991.
    CrossrefPubMedGoogle Scholar